A new option for patients with treatment-resistant migraine
- PMID: 35716681
- DOI: 10.1016/S1474-4422(22)00222-8
A new option for patients with treatment-resistant migraine
Conflict of interest statement
RO reports speaker fees from Eli Lilly, Novartis, and Teva; support for attending meetings or travel from Novartis and Teva; advisory board fees from Eli Lilly; and non-financial support from Allergan and Novartis. SS reports consultant, advisory board, or speaker fees from Abbott, Allergan, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Medscape, Medtronic, Novartis, Starmed, Teva, and Uriach.
Comment on
-
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. Lancet Neurol. 2022. PMID: 35716692 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical